INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH

A REVIEW OF MUCORMYCOSIS FOR POST COVID-19 COMPLICATION

Jeevitha lakshmi[1], Senthilkumar S R[1*], Venkatachalam Thangavel[2*], Sattanathan Kumar[3]

[1]*Arulmigu Kalasalingam College of Pharmacy, Krishnankovil, Virudhunagar- 626126, India.*
[2]*JKKMMRF's- Annai JKK Sampoorani Ammal College of Pharmacy B. Komarapalaym, Namakkal - 638 183.*
[3]*Paavai College of Pharmacy and Research, R. Puliyampatti, Namakkal- 637 018.*

ARTICLE INFO

Article history
Received 05/08/2021
Available online
31/08/2021

Keywords
Mucormycosis,
Covid-19,
Fungus Proliferation,
Diabetes Mellitus.

ABSTRACT

The pandemic coronavirus disease (COVID-19) continues to be a giant downside worldwide. Severe coronavirus disease (COVID-19) is presently managed with general glucocorticoids that improves survival rate in COVID-19 patients. Sadly, the in depth use of glucocorticoids will cause secondary microorganism or fungal infections. Whereas COVID-19 associated pulmonic aspergillosis is progressively recognized than mucormycosis. Mucormycosis is associate uncommon however serious infection that screw up the course of severe COVID-19. Mucormycosis is also a critical invasive fungal infection that arises notably in diabetic patients with or while not different underlying conditions like medical specialty malignancies or the need for solid-organ transplantation. Rhino-orbito-cerebral involvement is that the first website of mucormycosis, however the scarcity of signs may even be a reason for delayed identification. Contemporaneous hormone medical care most likely heightens the danger of mucormycosis. A high index of distrust and aggressive management is needed to boost outcomes.

Corresponding author
Venkatachalam Thangavel
JKKMMRF'S – Annai JKK Sampoorani Ammal
College Of Pharmacy
B. Komarapalayam–638 183.
TAMIL NADU
srsmpharm@gmail.com,
venkatmohana301108@gmail.com

*Please cite this article in press as **Jeevitha Lakshmi** et al. A Review of Mucormycosis for Post COVID-19 Complication. Indo American Journal of Pharmaceutical Research.2021:11(08).*

INTRODUCTION

Mucormycosis (Zygomycosis) is associate invasive zymosis, caused by opportunist and present fungi happiness to the category Phygomycetes, taxonomic category Zygomycetes, fungus order, family Mucoraceae; sometimes by the subsequent species: *Absidia corymbifera*, *Apophysomyces elegans*, *Mold roux ii*, *Rhizomucor pussillus*, and by species of the genus Saksenaea spp. It is non-inheritable by the institution or implantation of the flora spores among the oral, nasal and mucous membrane (rhino-orbito-cerebral), by inhalation, or by the bodily function of contaminated food (1). Mucormycosis is caused by a growing range of members of the fungus order. It's associated with mobile infection; primary malady is initiated within the higher or lower metabolic process tracts. That is related to the clinical development of inflammation, rhino cerebral mucormycosis, or pulmonic infection. Risk factors for the event of mucormycosis embody diabetic ketoacidosis; leucopenia; protein-calorie malnutrition; and bronzed diabetes, with or while not the concomitant use of deferoxamine (2). Mucormycosis is associate critical communicable disease, that affects principally upset patients owing to diabetic acidosis, neutropenia, organ transplantation, and/or enlarged blood serum levels of obtainable iron. Owing to the increasing prevalence of DM, cancer and organ transplantation, the quantity of patients in danger for this deadly infection is increasing (3). Despite aggressive medical care, which has disfiguring surgical procedure and regularly connected cyanogenetic antifungal medical care, the general fatality rate is high. New methods to forestall and treat mucormycosis area unit desperately required. Understanding the pathological process of mucormycosis and therefore the host response to invasive hyphae ultimately can give targets for novel therapeutic interventions (4). Mucormycosis is an aggressive, usually fatal, zymosis occurring in patients with egregious diabetic acidosis. The rhino cerebral kind presents with headache, rhinorrhea, and development of Black Death intranasal or intraoral lots. Progression will cause orbital redness, orbital apex syndrome, sinus cavernous syndrome, and central nervous system (CNS) involvement with lethargy, paresis and death. The identification is created histologically, because it is invasion and future tissue reaction, instead of the mere presence of this present organism, that denotes infection. Mucormycosis will happen as six completely different syndromes: rhino cerebral, pulmonary, epithelial duct, CNS, body covering and disseminated forms. Histologically, mold is characterized by fungi with thick-walled, nonseptated hyphae with branching at right angles. Histologically, malady is known as invasion on the elastic plate of blood vessels with future occlusion and tissue mortification. This permits embolization, similarly as localized pathology that promotes more fungus growth. Factors predisposing to invasive mold embody immunocompromised, poorly controlled DM, hematological malignancies, severe burns, nephritic disease, AIDS and induced immune suppression when organ transplantation. Acidosis and hyperglycemia area unite a perfect setting for fungus growth, as a result of such metabolic conditions inhibit the affinity and effectiveness of macrophages, fixing host defense mechanisms. Deferoxamine, associate agent employed in qualitative analysis patients for the treatment of aluminum or bronzed diabetes, it is an extra predisposing issue. It is thought that the mould spores will take up iron from the deferoxamine chelate, with future growth stimulation (5).

The mortality of mucormycosis remains high. Treatment includes antifungal agents together with surgical intervention. The sole new agent with activity against fungus order is isavuconazole, however it doesn't appear to supply important blessings over historical initial line medical care of antibiotic drug B-based medication or Posaconazole. The aim of the many researchers is to search out new ways for creating the identification of mucormycosis earlier, as early identification of mucormycosis ends up in improved survival (6). This paper can review the clinical manifestations, identification and treatment of mucormycosis related to DM and COVID-19.

Mechanism

Neutrophils play a serious role in destroying flora hyphae, once spores germinate.

↓

In host defense mechanisms, macrophages and monocytes conjointly play a task against fungi inflicting mucormycosis (specifically alveolar macrophages forestall germination of spores) (7)

↓

Therefore, mucormycosis develops solely in immunological disorder patients. World Health Organization lack these defense mechanisms.

↓

Treatment of corticosteroids, symptom and pathology have conjointly been legendary to hinder immunity (specifically the actions of somatic cell cells) (8)

↓

In order to cause illness, the agent of mucormycosis should acquire spare iron for growth from the host, evade host somatic cell defense mechanisms and access vasculature to circulate.

In immunological disorder hosts, iron is free from sequestering proteins creating it obtainable to fungi for growth within the body (9).

Acidosis conditions cut back the iron-binding capability, that disrupts the capability of globulin to bind iron, in all probability by proton-mediated displacement of metallic element iron from globulin (10)

Fungi will acquire iron from the host by victimisation high-affinity iron permeases or low-molecular-weight siderophores (iron chelators) (11).

Lack of neutrophils and phagocytes results in fungal proliferation (12)

Fungi inflicting mucormycosis, damages the epithelial tissue cells, leading to vascular invasion, sequent dissemination and tissue gangrene.

R. oryzae spores (i.e., pregerminated spores) have the flexibility to connect themselves to subendothelial matrix proteins as well as laminin and kind IV scleroprotein (13, 14). Glucose regulated macromolecule seventy-eight (GRP78) acts as a receptor that stimulate the flexibility of Mucorales to penetrate epithelial tissue cells.

Increased concentrations of aldohexose and iron, will increase GRP78 expression and ensuing invasion and injury of epithelial tissue cells in a very receptor-mediated manner (15). These findings probably make a case for the distinctive inclination of diabetic acidosis to mucormycosis.

DIAGNOSIS

At least four factors might contribute to a delay in diagnosis. First, an occasional index of suspicion might delay initiation of the suitable diagnostic analysis. Fungal infections square measure typically not thought-about till conventional treatment for a microorganism method has failing. Second, till recently, tissue samples for fungi cultures were homogenized, a deadly method to several mold species. Current tissue handling techniques, however, lead to a better yield of positive cultures. Third, thirty ninth of patients had a concomitant microorganism or infection, seventy four of that were microorganism respiratory organ pathogens. Since several biological science laboratories don't pursue extra pathogens once one is known, fungi cultures aren't routinely performed in patients with a diagnosed microorganism respiratory disorder. Finally, the unhealthful fungi typically can't be known with typical culture techniques. Therefore invasive diagnostic procedures, with their attendant risks and complications, square measure typically needed to get an adequate tissue sample (16). Since invasion of blood vessels may be a major pathologic manifestation of mucormycosis, areas of occlusion, hemorrhage and pathology square measure vital clues within the medical diagnosis of mucormycosis. Mucormycosis is additionally aggressive within the tract and therefore the CNS; fast progression of the infection and therefore the associated tissue injury may be a hallmark of the illness. Patients World Health Organization have aspergillosis will gift with findings of the tract and skin that square measure kind of like those seen in patients World Health Organization have mucormycosis. Culture and pathological examination of diagnostic assay specimens is, thus, the sole definitive thanks to differentiate between mucormycosis and aspergillosis. Similarly, bound gram negative bacilli, particularly Pseudomonas, will cause vasculitic lesions in skin or in innards that mimic lesions made by Mucorales.

The results of an MRI scan may additionally reveal abnormalities in concerned structures. Sinus involvement could also be noted as tissue layer thickening or by the presence of secretions. Venous occlusion and occlusion of different vessels could also be incontestible by failure of the structures to boost and this azole has been discontinued3. The activity of 1-triazole antifungal in experimental mucormycosis ought to prompt analysis of different agents for this indication(17). Microbiological studies were performed on tissue biopsies, inoculated on Sabouraud's agar, incubated at 30°C and therefore the sample was examined microscopically. Fungi growth was studied macroscopically at 37°C and 45°C once staining with lactofuchsin. Once four days, colonies of mold oryzae were seen growing on the media. Special stains for flora hyphae: PAS and GMS were positive. Aseptate, branching broad primarily based flora hyphae, areas of gangrene at the side of epitheloid cell granulomas comprising of epitheloid cells, multinucleated large cells and chronic inflammatory cell infiltrate were seen[18] .

SYMPTOMS OF MUCORMYCOSIS:

The symptoms of mucormycosis depend on where in the body the fungus is growing. If you have symptoms that you think are related to mucormycosis.

RHINICEREBRAL MUCORMYCOSIS

1.One sided facial sewelling
2.Head ache
3.Nasal or sinus congestion
4.Black lesion on nasal bridge or upper inside of mouth that quickly become more severe
5.Fever

PULMONARY MUCORMYCOSIS

1.Fever
2.Cough
3.Chest Pain
4.Shortness of breath

CUTANEOUS MUCORMYCOSIS

It can occur like blister or ulcer and the infected area may turn black. Other symptoms include pain, warmth, excessive redness or swelling around a wound (19,20).

ANTIFUNGAL THERAPY

The general principles of treatment of mucormycosis are appropriate surgical debridement for infected tissue and appropriate antifungal therapy. Early diagnosis is important because small, focal lesions are surgically excised before they progress to involve critical structures or disseminated.

RHINOCEREBRAL MUCORMYCOSIS

Early surgical excision of the infected sinuses and appropriate debridement of the retro orbital space can often prevent the infection from extending into the eye.

PULMONARY MUCORMYCOSIS

Surgical treatment plus antifungal treatment also greatly improves outcomes compared to the use of antifungal therapy alone.

CUTANEOUS MUCORMYCOSIS

It treated with aggressive surgical debridement and adjunctive antifungal therapy. If the patient survives the acute phase of the disease major reconstructive surgery may be necessary (21).

THERAPY

THERAPY	ANTIFUNGAL DRUGS	PROS
Established therapies	Amphotericin B deoxycholate	Improved CNS penetration
	Liposomal amphotericin B	High dose LAmB(15mg/kg/day) Superior to AmB(1mg/kg/day)
	Amphotericin B lipid complex	Less toxic than AmB
Investigational/Adjunctive therapies	1.Itraconazole 2.posaconazole 3.caspofungin 4.Iron chelation 5.Hyperbaric oxygen 6.Cytokin therapy	

Mucormycosis related to Covid-19:

The pandemic illness Covid-19, caused by the deadly corona virus is presently managed with general glucocorticoids. Sadly, it paves the manner for expedient zymosis for such patients (22). Otorhinolaryngology has been associated with the pandemic illness since its evolution (23). The declaration of dysomia as a typical marker that is diagnosed with cavum swab has been relevant to the detection of virus that isolates from cavity (24). A multiplex reciprocity of things that embody any previous metabolism pathology and systematic immune alterations of Covid-19 infection itself could cause secondary infections, that are more and more being recognized seeable of their impact on morbidity and mortality (25). Critically sick patients, particularly those admitted to medical care units and people United Nations agency need mechanical ventilation or United Nations agency had an extended length of hospital keep as long as fifty days, were additional probably to develop flora co-infections (26). In contrary, 2 patients old-time cluster 25-30, with history of covid, treated by home isolation with no history of taking steroid medications or given atomic number 8, rather had diabetes are developed with mucormycosis.

It clearly means the danger of flora growth isn't solely hospital nonheritable however additionally because of lack of private hygiene (repeated usage of cotton masks causes wetness stagnation) furthermore as weak system whereas taking antiviral medication that together ends up in the event of this dreadful illness (27)

Eventhough the deadly second wave of COVID-19 ravages Asian nation, doctors are currently news a rash of cases involving a rare infection - additionally referred to as the " black plant life " - among convalescent and recovered Covid-19 patients. aside from medical specialty treatment cannulization is finished through nasal route for the evacuation of the harmful plant life mucormycetes. This aggressive infection affects the nose, eye and generally brain. In severe cases, removal of the attention is needed for the survival of the victim (28). The intense infection has to be treated with prescription antifungal drugs, typically antibiotic drug B, posaconazole or isavuconazole. These medicines are given either intravenously (antibiotic drug B, posaconazole, isavuconazole) or orally (posaconazole, isavuconazole). alternative medicines, as well as fluconazole and echinocandins, don't work against the fungi mucormycetes(29). As mentioned earlier, it needs surgery to chop away the infected tissue.



[A] Interior fornix incision marked and retraction sutures taken. [B] Interior fornix incision taken, lateral canthotomy and inferior cantholysis done. [C] Dissection done in preseptal plane. [D] Septum incised and orbit approached along medial wall. Inferior and medial rectal muscles tagged. [E] Intraconal space entered between two muscles. [F] Debridement of Intraconal space (30).

Mucormycosis associated with Diabetes mellitus:

Mucormycosis is a fulminant and invasive fungal infection that can occur in patients with manifold precipitating factors. Uncontrolled diabetes mellitus is one of the most predominant components of them which is followed by immunosuppressive therapy with steroids. Despite hyperglycemia and acidosis, several other unknown factors may predispose diabetes mellitus to this dreadful infection (31). It is one of the most expeditiously progressing as well as devastating form of fungal infection in humans which usually begins in the nose and paranasal sinuses. The fungus assaults the arteries, leading to thrombosis that subsequently causes necrosis of hard and soft tissues (32). Rhino-orbital and Rhino-cerebral are the two forms of the disease. Early recognition and treatment are essential since it leads to death within few days. The increasing frequency of the infection is highly related to the immune deficiency of the patient (33). Hence mucormycosis remains a severe infectious disease in diabetic patients with a high mortality rate. The clinical diagnosis is often difficult and it gets delayed. It should be underlined that in diabetics, physicians should always pay special attention to the infections within facial skeleton, where a surgery is done usually to remove the infected tissues. Physician's role is vital especially for patients who do not respond to antibiotic therapy. Aggressive diagnostic procedures are required for histomicrobiological studies to confirm the disease. An early diagnosis, combined with medical and surgical treatments, is necessary to increase the outcome (34).

DISCUSSION

Mucormycosis or Zygomycosis is an uncommon and aggressive fungal infection that usually affects patients, it alters the immunological system of the human body. Mucormycosis is a fungal infection with high mortality and its rising incidence associated with covid-19 affected or recovered patients. Mucoraceae are ubiquitous saprophytic fungi. They are common inhabitants of decaying matter. It is also found in bread, soil, air, dust and hospital ward rooms. They also usually affects due to the use of air conditioners. The organisms are potent in the temperature climates (35). Mucormycosis is diagnosed appropriately histologically when it is broad shaped, irregular shaped, non-septate hyphae with right angle branching. It is seen in an invading tissue. Frequently, arterial invasion causes infarction. Speciation requires culture of the fungus and the advice of a mycologist, who has good interest in the Mucorales. This study found a dramatic improvement in prognosis in recent years, with 73% of survival of cases diagnosed since 1970 compared with 6% survival before 1970.The improved prognosis can be attributed to improved premortem diagnosis leading to agressive surgery and amphotericin B administration. There has been no major shift in the pattern of anatomic involvement by the disease to account for the improved prognosis, although all the cases of disseminated mucormycosis, which is uniformly fatal, occured before 1970.Perhaps mucormycosis is now being diagnosed and treated early enough to prevent dissemination (36).

Mucormycosis is rare opportunistic fungal infection characterized by infarction and necrosis of host tissues that results from invasion of the vasculature by hyphae. The most common clinical presentation of mucormycosis is rhino orbital cerebral infection, believed to be secondary to inhalation of spores into the paranasal sinuses of the susceptible host. The predisposing situations for mucormycosis include diabetes, systemic corticosteroid use, neutropenia, hematologic malignancies, stem cell transplant and immunocompromised individuals. Seventy percent of rhino orbital cerebral mucormycosis cases have been found to be in patients with diabetes mellitus, most of whom had also developed ketoacidosis at the time of presentation. Infection usually presents with acute sinusitis, fever, nasal congestion, purulent nasal discharge and headache. All the sinuses become involved, and contagious spread to adjacent structures such as the palate, orbit and brain results in clinical symptoms. For example, Spread of infection from the ethmoid sinus to the frontal lobe results in obtundation. Clinical suspicion and early treatment with surgical debridement are key to preventing morbidity in this often fatal condition. Histopathology, direct microscopy and culture from clinical specimens are the major diagnostic modalities for mucormycosis. The survival only depends on the early recognition of mucormycosis. Early clinical manifestations to identify are melanotic or blood tinged nasal discharge, black necrotic crusting on the nasal septum and turbinates, perforation of the septum and palate,p roptosis, periorbital edema, and numbness with eye involvement, and cranial neuropathy with intracranial extension. Early radiographic changes include thickening of the soft tissue lining of the sinuses without apparent fluid level (37). The most common risk factors being diabetes mellitus,immunosuppressive therapy,leukemias,neutropenias,patients with neutrophil dysfunction,hematopoetic stem cell transplantation,diabetic ketoacidosis,iron-overload and HIV/AIDS.They are some identified risk factors (30). Mostly and commonly affects the sinuses or the lungs after inhaling fungal spores from the air.It can also occur on the skin after a cut,burn,or other type of skin injury(38). Surgical debridement of the infected area should be performed as soon as possible once the diagnosis is confirmed. Amphotericin-B deoxycholate remains the anti-fungal treatment of choice to start, with its liposomal preparations because of decreased nephrotoxicity (39). In cases of intolerance to amphotericin therapy, Posaconazole will be suitable for an alternative option. Prognosis remains poor even with aggressive surgery and intravenous anti-fungal therapy, with reported mortality rates of 33.3-80 percent, going upto 100 percent in disseminated infections (40).

Our review of the literature indicates that this is the first documented mucormycosis in combination with covid-19 infection. It is impossible to know for certain whether these patients covid-19 infection was contributory to the illness or merely coincidental. In our opinion, the patients with severe immunocompromised state from untreated diabetes and ultimately diabetic ketoacidosis is what made the patient susceptible to contract both mucormycosis and covid-19 (41).

CONCLUSION

We are learning more about the new and long-term manifestations of the covid-19 infection. Its association with invasive mucormycosis sinusitis is dangerous. And it must be given serious consideration. Uncontrolled diabetes and over zealous use of steroids are two of the main factors aggravating the illness, and both of these must be properly checked. If infected, early surgical intervention and intravenous anti-fungal treatment should be sought for management, as a good prognosis and less fulminant disease course can be achieved in cases of post-coronavirus mucormycosis. Research is needed for better prevention and management infections in covid-19 patients. The use of prophylactic treatment protocols for the same needs to be assessed and guidelines need to established in order to reduce morbidity. Moreover, use of immuno-suppressants should be more judicious with continuous monitoring.

ACKNOWLEDGEMENT

Authors are thankful to, Arulmigu Kalasalingam College Of Pharmacy Krishnankovil Srivilliputtur -626126 Tamil Nadu, India for providing all the facilities and support to carry out the work.

REFERANCE

1. Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021 Feb;13(2).
2. Sugar AM. Mucormycosis. Clinical infectious diseases. 1992 Mar 1;14(Supplement_1): S126-9.
3. Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Medical mycology. 2018 Jan 1;56(1):29-43.
4. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clinical Infectious Diseases. 2012 Feb 1;54(suppl_1):S16-22.
5. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. The Laryngoscope. 1997 Jul;107(7):855-62.
6. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Medical mycology. 2018 Apr 1;56(suppl_1):S93-101
7. Waldorf AR. Pulmonary defense mechanism against opportunistic fungal pathogens. Immunology serious. 1989 Jan 1;47:23-71.
8. Spellberg B, Edwards J, Ibrahim A. Novel perspective on mucormycosis: pathophysiology, presentation, and management. Clinical microbiology reviews. 2005 Jul 1;18(3):556-69.
9. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis transferrin and iron availability. Diabetes. 1982 Dec 1;31 (12): 1109–14.
10. Ibrahim A, Spellberg B, Edward Jr J. Iron Acquisition: a novel prospevctive on mucormycosis pathogenesis and treatment. Current opinion in infectious diseases. 2008 Dec;21(6):620
11. Howard DH. Acquisition, transport, and storage of iron by pathogenic fungai. Clinical microbiology reviews. 1999 Jul;12(3):394
12. Boelaert JR, de Locht M, Van cutsem J, Kerrels V, Cantinieaux B, Verdonck A, Van Landuyt HW, Schneider YJ. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. The journal of clinical investigation. 1993 May 1;91(5):1979-86.
13. Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D . "Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components". European journal of cell biology.1996 May 1;70(1): 76-83.
14. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edward Jr JE. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infection and immunity. 2005 Feb;73(2):778
15. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, Edwards JE, Filler SG, Ibrahim AS. The endothelial cell receptor DRP78 is required for mucormycosis pathogenesis in investigation. 2010 Jun 1;120(6):1914-24.
16. Greene R. Opportunistic pneumonias. Sem Roent 1980;15: 50-72
17. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: a dinicopathologic study of 33 cases. Medicine (Baltimore) 1986;65:11323.
18. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. International Journal of Surgery Case Report. 2021 May 4:105957
19. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemology and clinical manifestations of mucormycosis. Clin Infect Dis 2012 Febl;54 Suppl 1:S23-34
20. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301
21. Brad Spelling, John Edwards Jr. and Ashraf Ibrahim Clin. Microbiol. Rev. 2005, (18)3:556
22. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti A, Agarwal R. Coronavirus disease (Covid-19)associated mucormycosis (CAM): case report and systemic review of literature Mycopathologia. 2021 Feb 5:1-0.
23. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. The Journal of laryngology and otology. 2021 Apr 8:1-6.
24. Frazier KM , Hooper JE , Mustafa HH, Stewart CM. SARS-CoV virus isolated from the mastoid and middle ear : implications for Covid-19 precautions during ear surgery. JAMA -Otolaryngol Head Neck Surg -2020 ;146 : 964- 6
25. Chen N , Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological & clinical characteristics of 99 cases of 2019 novel Coronavirus pneumonia in Wuhan, China : a descriptive study. The lancet. 2020 Feb 15:395(10223):507-13.
26. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China, a single-centered, retrospective, observational study, Lancet Respir Med 2020 ; 8 : 475 -81.
27. CDC(Centers for Disease control and prevention) : Mucormycosis https://www.cdc.gov
28. Dyer O. Covid-19: India sees record deaths as “black fungus” spreads fear.
29. CDC (Centers for disease control and prevention) : fungal diseases- Mucormycosis
30. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. International Journal of Surgery Case Reports. 2021 May 4:105957.
31. Afroze SN, Korlepara R, Rao GV, Madala J. Mucormycosis in a diabetic patient: a case report with an insight into its pathophysiology. Contemporary clinical dentistry. 2017 Oct;8(4):662.
32. Nirmala SV, Lalitha V, Sivakumar N, Kumar KK, Srikanth M. Mucormycosis associated with juvenile diabetes. Journal of Indian Society of Pedodontics and Preventive Dentistry. 2011 Dec 1;29(6):87.
33. Shinde RV, KaRande GS, Mohite ST, Patil SR. Rhino-orbital mucormycosis in diabetes mellitus. Journal of clinical and diagnostic research: JCDR. 2013 Jun;7(6):1145.
34. Mallis A, Masttonikolis SN, Naxakis SS, Papadas AT, Rhinocerebral mucormycosis: an update European Review for Medical and Pharmacological Sciences 2010 14 : 987 – 92.

35. Kumar G, Arora K. Epidemiological Analysis of an Outbreak of Coronavirus(COVID-19) Disease in the world. InHealth Informatics and technological solutions for coronavirus (COVID-19) 2021Apr 13 (pp. 185-191). CRC Press.
36. Michael RC, Micheal JS, Ashbee RH, Mathews MS. Mycological profile of fungal sinusitis: An audit of specimens over a 7 year period in a tertiary care hospital in Tamil Nadu. Indian Journal of pathology and microbiology. 2008 Oct 1;51(4):493.
37. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environmental research. 2020 Jun 13:109819.
38. Ferguson,BJ.Definitions of fungal rhinosinusitis.Otolaryngol clin North AM 2000;33:227-35.
39. Sugar AM. Mucormycosis. Clinical infectious disease. 1992 Mar 1;14(Supplement_1):S126-9.
40. Meyers BR,Wormser G,Hirschman SZ,Blister A Rhinocerebaral mucormycosis.Premortem diagnosis and therapy.Arch intern Med 139(5);557-60,1979.
41. Pastore PN. Mucormycosis of maxillary sinus and diabetes mellitus: report of case with recovery.South Med J 60: